GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Development
British drugmaker GSK targets £1.9 billion in savings over three years to fund late-stage studies and R&D investments. GSK announced a £1.9 billion ($2.52 billion) cost-savings program to streamline operations and redirect funds toward late-stage drug development. The init